| Name | Olverembatinib dimesylate |
| Description | Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I). |
| Cell Research | Cells in the logarithmic phase are plated in 96-well culture dishes. Twenty-four hours later, cells are treated with the corresponding compounds or vehicle control at the indicated concentration for 72 h. CCK-8 is added into the 96-well plates (10 μL/well) and incubated with the cells for 3 h. OD450 and OD650 are determined by a microplate reader. Absorbance rate (A) for each well is calculated as OD450 – OD650. The cell viability rate for each well is calculated as V% = (As – Ac)/(Ab – Ac) × 100%, and the data were further analyzed using Graphpad Prism5. The data are the mean value of the three experiments. As is the absorbance rate of the test compound well, Ac is the absorbance rate of the well without either cell or test compound, and Ab is the absorbance rate of the well with cell and vehicle control.(Only for Reference) |
| Kinase Assay | FRET-Based Z′-Lyte Assay Detecting Peptide Substrate Phosphorylation: The kinases ABL1, ABL1(E255K), ABL1 (G250E), ABL1(T315I), and ABL1(Y253F) are P3049, PV3864, PV3865, PV3866, and PV3863 are full-length human recombinant protein expressed in insect cells and histidine-tagged. Inhibition activities of inhibitors against Abl1 and its mutants are performed in 384-well plates using the FRET-based Z′-Lyte assay system. Briefly, the kinase substrate is diluted into 5 μL of kinase reaction buffer; and the kinase is added. Compounds (10 nL) with indicated concentrations are then delivered to the reaction by using Echo liquid handler, and the mixture is incubated for 30 min at room temperature. Then 5 μL of 2X ATP solution is added to initiate the reaction, and the mixture is further incubated for 2 h at room temperature. The resulting reactions contains 10 μM (for wild-type Abl1, and mutants Y253F, Q252H, M351T, and H396P) or 5 μM (for mutants E255K, G250E, T315I) of ATP, 2 μM of Tyr2 Peptide substrate in 50 mM HEPES (PH 7.5), 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.0247 μg/mL Abl1, and inhibitors as appropriate. Then, 5 μL of development reagent is added, and the mixture is incubated for 2 h at room temperature before 5 μL of stop solution is added. Fluorescence signal ratio of 445 nm (Coumarin)/520 nm (fluorescin) is examined on an EnVision Multilabel Reader. The data are analyzed using Graphpad Prism5. The data are the mean value of three experiments. |
| In vitro | Administering 20 mg/kg of GZD824 daily inhibits tumor growth in syngeneic transplantation mice bearing Ba/F3 cells expressing Bcr-AblWT and BCR-AblT315I. Daily doses of 5 and 10 mg/kg GZD824 show a dose-dependent inhibition of tumor growth in xenograft models of K562 and KU812 tumors, without causing mortality or weight loss. |
| In vivo | GZD824 effectively inhibits the activation of Bcr-Abl and its downstream targets, Crk1 and STAT5, in leukemia cells in a concentration-dependent manner. Its efficacy in inhibiting the proliferation of Ba/F3 cells expressing the Bcr-Abl T315I mutation and another 14 Bcr-Abl mutations associated with resistance aligns closely with results from biochemical kinase inhibition and protein binding affinity experiments. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : 92 mg/mL (126.9 mM)
DMSO : 93 mg/mL (128.3 mM)
|
| Keywords | region-Abelson | phosphorylated | imatinib | Olverembatinib dimesylate | inhibit | linase | Inhibitor | HQP-1351 | nonphosphorylated | breakpoint | resistance | GZD-824 Dimesylate | HQP 1351 | HQP1351 dimesylate | Olverembatinib Dimesylate | GZD 824 Dimesylate | GZD-824 | GZD824 | Bcr-Abl | Bcr-Abl(T315I) | GZD 824 | cluster | Olverembatinib |
| Inhibitors Related | Imatinib Mesylate | Bosutinib hydrate | Pivanex | Dasatinib | GNF-5 | Ponatinib | Nilotinib monohydrochloride monohydrate | KW-2449 | Nilotinib | Dasatinib monohydrate | Imatinib | Masitinib |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
